jetcityimage/iStock Editorial via Getty Images Takeda ( NYSE: TAK ) announced on Monday the approval of its post-transplant cytomegalovirus (CMV) infection treatment, Livtencity (maribavir) in Japan. Livtencity is the first and only post-transplant anti-CMV treatment to be approved in Japan that targets and inhibits pUL97 kinase and its natural substrates. CMV is a common and serious post-transplant infection and can lead to secondary infections and consequences such as transplanted organ loss and failure.
The approval is based on the results of the Phase 3 Solstice trial that compared the safety and efficacy of Livtencity with alternative antiviral treatments for patients with CMV infection/disease. More on Takeda Pharmaceutical Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript Takeda Pharmaceutical Company Limited 2023 Q4 - Results - Earnings Call Presentation Takeda gets EU approval for Fruzaqla for colorectal cancer Ovid stock plunges 66% on failed studies for soticlestat.